abiraterone acetate (ATRS-2002) / Halozyme - LARVOL DELTA

Breaking FDA approval - niraparib-abiraterone for BRCA-mutated #prostatecancer! One hybrid pill, ease of treatment. Congrats to the #MAGNITUDE team @JanssenUSOncMed ! https://onclive.com/view/fda-approves-niraparib-plus-abiraterone-acetate-for-mcrpc @PCFnews @urotoday @ZEROCancer

Examining Survival Rates in Prostate Cancer: Exploring the STAMPEDE Platform, Journal Club - Rashid Sayyid & Zachary Klaassen (Urotoday) - "...and Zach Klaassen discuss recent findings from the STAMPEDE platform regarding the efficacy of abiraterone acetate plus prednisolone, with or without enzalutamide, for patients with metastatic prostate cancer initiating ADT. Drawing on data from two randomized Phase III trials, the pair examine long-term outcomes."

Video

Phase 1 Study of ATRS-2002 in Healthy Male Adults (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Syneos Health | N=32 ➔ 0 | Trial completion date: Dec 2023 ➔ Apr 2023 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Sep 2023 ➔ Apr 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical Advantage Over Enzalutamide Alone in First-Line Treatment of mCRPC (ESMO.org) - "The combination was associated with an unfavourable drug-drug interaction that increased abiraterone acetate clearance and with more adverse events. The combination of enzalutamide plus abiraterone acetate and prednisone is currently not recommended in routine clinical practice. The study findings are published by Dr. Michael J. Morris..."

Enzalutamide Plus Abiraterone Not Recommended for Patients With Metastatic Castration-Resistant Prostate Cancer (HMP Global) - "Journal of Clinical Oncology associate editor, Michael A Carducci, MD...wrote that this trial 'has been long awaited and affirms current practice supporting single-agent androgen receptor signaling inhibitors as standard of care for metastatic castration-sensitive prostate cancer.'"

Media quote

Real-world time-to-castration resistance among patients with metastatic castration-sensitive prostate cancer initiating apalutamide, enzalutamide, or abiraterone acetate from an oncology database (AMCP 2023) - No abstract available.

The PCCTC at GU ASCO 2023 - "This year's ASCO GU Cancers Symposium, held 16-18 February in San Francisco, will feature abstracts from 12 different Prostate Cancer Clinical Trials Consortium (PCCTC) studies and its Germline Genetics Working Group....Rana McKay...FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)....Howard Scher. A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer..."

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam (Urotoday) - "...Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC."

Video

No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial - Cora Sternberg (Urotoday) - "Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment landscape for mHSPC has become increasingly complex during the last several years."

Video

Phase 1 Study of ATRS-2002 in Healthy Male Adults (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Syneos Health | Trial completion date: Dec 2021 ➔ Dec 2023 | Trial primary completion date: Nov 2021 ➔ Sep 2023

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Three-Drug Combination Boosts Survival in Men With Metastatic, Hormone-Sensitive Prostate Cancer (Patient Power) - '"The ideal candidate is someone who is newly diagnosed with advanced prostate cancer and high-volume disease,' Dr. Shore said. 'They have to be fit for chemotherapy. Essentially [they need] normal kidney and liver function, which the overwhelming majority of metastatic prostate cancer diagnoses tend to [have].'"

Media quote

PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer (THE ASCO POST) - '"The study included men with metastatic castration-resistant prostate cancer irrespective of whether they had bone or soft-tissue metastasis. We are targeting men with germline or tumor HRR genetic alterations [with this combination] because they have a worse prognosis. Our goal is not just to achieve a statistically significant benefit, but a clinically meaningful one,' noted Eleni Efstathiou, MD, in a separate interview with The ASCO Post."

Interview • Video

An 82-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer - Episode 3: Initial Treatment Options for mCRPC (Targeted Oncology) - "Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC)."

Video

Phase 1 Study of ATRS-2002 in Healthy Male Adults (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Syneos Health

Clinical • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor